Dofequidar

Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1) . Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].

Product Specifications

CAS Number

[129716-58-1]

Product Name Alternative

MS-209 (free base)

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Dofequidar.html

Concentration

10mM

Purity

98.17

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)CC3

Molecular Formula

C30H31N3O3

Molecular Weight

481.59

Precautions

H315, H319, H320

References & Citations

[1]Nokihara H, et al. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res. 2001 Jul;92 (7) :785-92.|[2]Katayama R, et al. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci. 2009 Nov;100 (11) :2060-8.